Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Daniel Anthony


Head of Experimental Neuropathology Laboratory

How mediators of the inflammatory response contribute to the outcome of spinal or brain injuries. How events in others organs, such as the liver, contribute to the outcome of brain injury or disease. In particular (with the Neuroimaging group), we are studying the mechanisms that give rise to the reactivation of a Multiple sclerosis-like lesions by a systemic inflammatory response. How brain injury contributes to the outcome of disease elsewhere in the body with a focus on how hepatic NFkB activity contributes to the acute phase response after CNS injury (with Dr Mann, Southampton). How inflammation affects brain serotonin function and the relevance to depression (with Dr Sharp and the Neuroimaging group).

False False

Dr Daniel Anthony joined the Department in 2004 from Southampton (1998-2004) and runs the Experimental Neuropathology Laboratory. The focus of the work of our laboratory is research to identify how inflammation contributes to the outcome of acute and chronic brain injury or infection. There is now considerable evidence to support the idea that inflammation contributes, in a deleterious manner, not only to the archetypal inflammatory disease of the brain, multiple sclerosis, but also to acute neurological diseases, such as stroke and head trauma, and to chronic neurodegenerative diseases, such as Alzheimer's disease, prion disease, and HIV-related dementia.

The laboratory is recognised both nationally and internationally and has close ties with Dr Sibson’s Experimental Neuroimaging Group at Radiation, Oncology and Biology (ROB), Oxford. Dr Anthony was a Glaxo graduate student in the Department of Surgery, University College London where he worked with Professor Paul Boulos examining the role of metalloproteinases in Inflammatory Bowel Disease. Following the completion of his PhD in 1994, Dr Anthony joined Professor Hugh Perry, then in Oxford, on a British Biotech Fellowship investigating metalloproteinase expression in the CNS. It was during this period that he became interested in the leukocyte-mediated mechanisms of neurodegeneration. Dr Anthony also held a position as retained lecturer at Trinity College Oxford in this period (1994-1998).